Etentamig for Newly Diagnosed Patients
Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2/3
- Enrollment
- 660 patients (estimated)
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2214
- NCT Identifier
- NCT07095452
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.